When a patient is diagnosed with metastatic breast cancer that has become resistant to hormone therapy, finding the right treatment path is vital. A new analysis of clinical trial data suggests that a specific enzyme called thymidine kinase (TKa) could serve as an important guide for doctors. This enzyme helps determine how well certain drugs work within the body.
Researchers looked at 555 patients with hormone receptor-positive, HER2-negative metastatic breast cancer. They compared two treatment paths: endocrine therapy combined with palbociclib versus capecitabine. The study found that patients who started with low levels of this enzyme lived longer and stayed stable on their treatment for a longer period. Specifically, those with low levels saw an average of 38.5 months of overall survival compared to 17.3 months in the group with higher levels.
While these findings are promising for identifying which patients might do better on specific drugs, it is important to note that this was a translational analysis of an existing trial. This means the data is used to understand how the body reacts to medicine rather than being the primary report of the study's goals. Talk to your doctor about how these markers might apply to your specific treatment plan.
